Wilms' Tumor 1 (WT1) Mutation Analysis

Understand what Wilms' Tumor 1 (WT1) Mutation Analysis signals

LOINC codes: 21742-2, 31208-2
Commercial laboratory assays: 1

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Wilms' Tumor 1 (WT1) Mutation Analysis

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Wilms' Tumor 1 (WT1) Mutation Analysis

Laboratory: Quest Diagnostics
Test code: 16896
Specimen: Blood
Fasting: Not stated
LOINC: 21742-2, 31208-2
Turnaround: Set up: Mon

Laboratory assay overview

WT1 mutations occur in up to 15% of patients with AML. Cytogenetically normal acute myeloid leukemia (CN-AML) is the largest subgroup of AML, which represents approximately 45% of adult patients with AML. A WT1 mutation at diagnosis is associated with poor, outcome; it independently predicts a higher risk of relapse when other molecular markers with established prognostic significance and clinical variables are taken into consideration.

View complete laboratory reference notes

Not detected

Quest Diagnostics test directory, test code 16896

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.